Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 363Precursor Cell Lymphoblastic Leukemia-Lymphoma 89Leukemia 61Neoplasms, Plasma Cell 60Lymphoma 59Recurrence 52Neoplasms 34Vomiting 33Lymphoma, Non-Hodgkin 32Immunoglobulin Light-chain Amyloidosis 27Lymphoma, Mantle-Cell 26Burkitt Lymphoma 26Nausea 22Lymphoma, Large B-Cell, Diffuse 21Leukemia, Lymphocytic, Chronic, B-Cell 21Waldenstrom Macroglobulinemia 19Prostatic Neoplasms 19Lymphoma, Follicular 18Hodgkin Disease 18Neoplasm Metastasis 14Breast Neoplasms 14Amyloidosis 12Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myeloid, Acute 11Carcinoma, Non-Small-Cell Lung 11Ovarian Neoplasms 9Lymphoma, Large-Cell, Immunoblastic 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell, Cutaneous 8Colonic Neoplasms 8

Interventions

midostaurin 2avapritinib 2Imatinib Mesylate 2sarilumab 1ripretinib 1nilotinib 1masitinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Thalidomide 1Ranitidine 1Interviews as Topic 1Ibuprofen 1Everolimus 1Diphenhydramine 1Dexamethasone 1Denosumab 1Calcium Dobesilate 1Brentuximab Vedotin 1Acetaminophen 1AK002 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mastocytosis, Systemic × Dexamethasone × Clear all
NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

City of Hope Medical Center

Phase 1 Completed
13 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡